Singapore, Nov. 14 -- Australia's Monash University spinout RAGE Biotech has raised $29 million in Series A funding, marking a major step toward translating RNA-based therapeutics for chronic inflammatory disease into the clinic.

Originating from the School of Translational Medicine within the Faculty of Medicine, Nursing and Health Sciences, RAGE Biotech leverages pioneering expertise in splice-switching oligonucleotide therapeutics and RAGE biology to advance a potential precision therapy for chronic obstructive pulmonary disease (COPD) and related inflammatory lung conditions.

The funding round was led by IP Group Australia and Hostplus, with participation from Monash Ventures. The capital will accelerate RAGE Biotech's lead program,...